New Zealand markets close in 2 hours 15 minutes
  • NZX 50

    10,991.11
    -6.81 (-0.06%)
     
  • NZD/USD

    0.6296
    -0.0008 (-0.13%)
     
  • NZD/EUR

    0.5948
    -0.0001 (-0.01%)
     
  • ALL ORDS

    6,908.20
    +14.60 (+0.21%)
     
  • ASX 200

    6,720.00
    +14.00 (+0.21%)
     
  • OIL

    110.89
    +1.32 (+1.20%)
     
  • GOLD

    1,824.60
    -0.20 (-0.01%)
     
  • NASDAQ

    12,008.24
    -97.61 (-0.81%)
     
  • FTSE

    7,258.32
    +49.51 (+0.69%)
     
  • Dow Jones

    31,438.26
    -62.42 (-0.20%)
     
  • DAX

    13,186.07
    +67.94 (+0.52%)
     
  • Hang Seng

    21,965.09
    -264.43 (-1.19%)
     
  • NIKKEI 225

    26,846.45
    -24.82 (-0.09%)
     
  • NZD/JPY

    85.0710
    -0.2700 (-0.32%)
     

Chimerix to Present at H.C. Wainwright Global Investment Conference

·1-min read
Chimerix, Inc.
Chimerix, Inc.

DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright Global Investment Conference made available on Tuesday, May 24, 2022 at 7:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com





Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting